New drugs for the treatment of diabetes part II: Incretin-based therapy and beyond

Silvio E. Inzucchi, Darren K McGuire

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs. (Circulation. 2008;117:574-584.)

Original languageEnglish (US)
Pages (from-to)574-584
Number of pages11
JournalCirculation
Volume117
Issue number4
DOIs
StatePublished - Jan 29 2008

Fingerprint

Incretins
Dipeptidyl-Peptidase IV Inhibitors
Thiazolidinediones
Glucagon-Like Peptide 1
Risk Reduction Behavior
Hypoglycemic Agents
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Glucose
Therapeutics
Surveys and Questionnaires

Keywords

  • Coronary disease
  • Diabetes mellitus
  • Drugs
  • Heart failure
  • Incretins

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

New drugs for the treatment of diabetes part II : Incretin-based therapy and beyond. / Inzucchi, Silvio E.; McGuire, Darren K.

In: Circulation, Vol. 117, No. 4, 29.01.2008, p. 574-584.

Research output: Contribution to journalArticle

@article{b7886de3794840fdae3740a193bb4214,
title = "New drugs for the treatment of diabetes part II: Incretin-based therapy and beyond",
abstract = "This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs. (Circulation. 2008;117:574-584.)",
keywords = "Coronary disease, Diabetes mellitus, Drugs, Heart failure, Incretins",
author = "Inzucchi, {Silvio E.} and McGuire, {Darren K}",
year = "2008",
month = "1",
day = "29",
doi = "10.1161/CIRCULATIONAHA.107.735795",
language = "English (US)",
volume = "117",
pages = "574--584",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - New drugs for the treatment of diabetes part II

T2 - Incretin-based therapy and beyond

AU - Inzucchi, Silvio E.

AU - McGuire, Darren K

PY - 2008/1/29

Y1 - 2008/1/29

N2 - This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs. (Circulation. 2008;117:574-584.)

AB - This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs. (Circulation. 2008;117:574-584.)

KW - Coronary disease

KW - Diabetes mellitus

KW - Drugs

KW - Heart failure

KW - Incretins

UR - http://www.scopus.com/inward/record.url?scp=41049110803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049110803&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.107.735795

DO - 10.1161/CIRCULATIONAHA.107.735795

M3 - Article

C2 - 18227398

AN - SCOPUS:41049110803

VL - 117

SP - 574

EP - 584

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -